WO2004033422A2 - Modulation of anxiety through blockade of anandamide hydrolysis - Google Patents

Modulation of anxiety through blockade of anandamide hydrolysis Download PDF

Info

Publication number
WO2004033422A2
WO2004033422A2 PCT/US2003/031844 US0331844W WO2004033422A2 WO 2004033422 A2 WO2004033422 A2 WO 2004033422A2 US 0331844 W US0331844 W US 0331844W WO 2004033422 A2 WO2004033422 A2 WO 2004033422A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
compound
group
alkyl
Prior art date
Application number
PCT/US2003/031844
Other languages
English (en)
French (fr)
Other versions
WO2004033422A3 (en
Inventor
Daniele Piomelli
Andrea Duranti
Andrea Tontini
Marco Mor
Georgio Tarzia
Original Assignee
The Regents Of The University Of California
Universita Degli Studi Di Urbino
Universita Degli Studi Di Parma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California, Universita Degli Studi Di Urbino, Universita Degli Studi Di Parma filed Critical The Regents Of The University Of California
Priority to CA2501506A priority Critical patent/CA2501506C/en
Priority to MXPA05003715A priority patent/MXPA05003715A/es
Priority to UAA200504339A priority patent/UA80841C2/xx
Priority to AU2003279877A priority patent/AU2003279877B2/en
Priority to EA200500615A priority patent/EA010267B1/ru
Priority to JP2004543510A priority patent/JP4515911B2/ja
Priority to EP03773201.3A priority patent/EP1558591B1/en
Publication of WO2004033422A2 publication Critical patent/WO2004033422A2/en
Publication of WO2004033422A3 publication Critical patent/WO2004033422A3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/56Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48Y being a hydrogen or a carbon atom
    • C07C275/54Y being a carbon atom of a six-membered aromatic ring, e.g. benzoylureas
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PCT/US2003/031844 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis WO2004033422A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA2501506A CA2501506C (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis
MXPA05003715A MXPA05003715A (es) 2002-10-07 2003-10-07 Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.
UAA200504339A UA80841C2 (en) 2002-10-07 2003-10-07 Fatty acid amide hydrolase inhibitors, pharmaceutical composition (variants) and method to treat appetite disorders, glaucoma, pain, and related neurological disorders (variants)
AU2003279877A AU2003279877B2 (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis
EA200500615A EA010267B1 (ru) 2002-10-07 2003-10-07 Модуляция тревоги через блокаду гидролиза анандамида
JP2004543510A JP4515911B2 (ja) 2002-10-07 2003-10-07 アナンダミド加水分解の遮断による不安の調節
EP03773201.3A EP1558591B1 (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41700802P 2002-10-07 2002-10-07
US60/417,008 2002-10-07

Publications (2)

Publication Number Publication Date
WO2004033422A2 true WO2004033422A2 (en) 2004-04-22
WO2004033422A3 WO2004033422A3 (en) 2004-07-29

Family

ID=32093946

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031844 WO2004033422A2 (en) 2002-10-07 2003-10-07 Modulation of anxiety through blockade of anandamide hydrolysis

Country Status (11)

Country Link
US (3) US7176201B2 (US08003693-20110823-C00093.png)
EP (1) EP1558591B1 (US08003693-20110823-C00093.png)
JP (1) JP4515911B2 (US08003693-20110823-C00093.png)
KR (1) KR20050088992A (US08003693-20110823-C00093.png)
CN (1) CN100408556C (US08003693-20110823-C00093.png)
AU (1) AU2003279877B2 (US08003693-20110823-C00093.png)
CA (1) CA2501506C (US08003693-20110823-C00093.png)
EA (1) EA010267B1 (US08003693-20110823-C00093.png)
MX (1) MXPA05003715A (US08003693-20110823-C00093.png)
UA (1) UA80841C2 (US08003693-20110823-C00093.png)
WO (1) WO2004033422A2 (US08003693-20110823-C00093.png)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006000324A2 (en) * 2004-06-23 2006-01-05 F. Hoffmann-La Roche Ag New mao-b inhibitors
EP1849773A1 (en) * 2005-02-17 2007-10-31 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
WO2008022976A1 (en) * 2006-08-21 2008-02-28 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of a faah inhibitor
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
WO2008042892A2 (en) * 2006-10-02 2008-04-10 N.V. Organon Fatty acid amide hydrolase inhibitors for energy metabolism disorders
JP2008520740A (ja) * 2004-11-23 2008-06-19 ピーティーシー セラピューティクス, インコーポレイテッド Vegf産生を阻害する活性因子としての置換されたフェノール
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2008135041A1 (de) * 2007-05-08 2008-11-13 Schebo Biotech Ag Adamantyloxyamin-derivate und verwandte verbindungen als nmda und/oder dpp-4 modulatoren zur behandlung von zns-erkrankungen und diabetes
WO2008147553A1 (en) * 2007-05-25 2008-12-04 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
WO2010007966A1 (ja) 2008-07-14 2010-01-21 アステラス製薬株式会社 アゾール化合物
WO2010053120A1 (ja) 2008-11-06 2010-05-14 アステラス製薬株式会社 カルバメート化合物又はその塩
WO2010055267A1 (fr) * 2008-11-14 2010-05-20 Sanofi-Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique
FR2941696A1 (fr) * 2009-02-05 2010-08-06 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2011030798A1 (ja) 2009-09-09 2011-03-17 大日本住友製薬株式会社 8-オキソジヒドロプリン誘導体
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
FR2955580A1 (fr) * 2010-01-28 2011-07-29 Sanofi Aventis Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
US20130137710A1 (en) * 2010-05-25 2013-05-30 Symrise Ag Cyclohexyl carbamate compounds as active anti-cellulite ingredients
US20130217764A1 (en) * 2010-07-28 2013-08-22 Daniele Piomelli Peripherally restricted faah inhibitors
EP2744778A2 (en) * 2011-08-19 2014-06-25 The Regents of the University of California Meta-substituted biphenyl peripherally restricted faah inhibitors
WO2015007615A1 (en) * 2013-07-18 2015-01-22 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
US9000010B2 (en) 2010-01-20 2015-04-07 Sanofi Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
US9822068B2 (en) 2014-04-07 2017-11-21 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923738D0 (en) * 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
US20050054730A1 (en) * 2001-03-27 2005-03-10 The Regents Of The University Of California Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha
US7750030B2 (en) * 2001-03-29 2010-07-06 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
AU2003296895A1 (en) * 2002-08-20 2004-05-04 The Regents Of The University Of California Combination therapy for controlling appetites
MXPA05003715A (es) * 2002-10-07 2005-09-30 Univ California Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.
EP1608319A4 (en) * 2003-04-03 2007-02-28 Univ California IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE
EP1677780A4 (en) * 2003-10-16 2007-05-02 Univ California DIETETIC COMPOSITIONS AND OTHER COMPOSITIONS, COMPOUNDS AND METHODS FOR ORGANIC LIPID REDUCTION, APPETILE CONTROL, AND METABOLISM MODULATION OF FATTY ACIDS
FR2865205B1 (fr) * 2004-01-16 2006-02-24 Sanofi Synthelabo Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique
FR2866886B1 (fr) * 2004-02-26 2007-08-31 Sanofi Synthelabo Derives d'aryl-et d'heteroaryl-akylcarbamates, leur preparation et leur application en therapeutique
EP1765311A4 (en) 2004-03-16 2009-04-29 Univ California REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
AU2005295167B2 (en) * 2004-10-20 2012-05-10 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
KR100693528B1 (ko) * 2004-10-29 2007-03-14 주식회사 팬택 전원 지연 인가 기능을 가지는 무선통신 단말기
US20090082435A1 (en) * 2005-04-28 2009-03-26 The Regents Of The University Of California Methods, Compositions, And Compounds For Modulation Of Monoacylglycerol Lipase, Pain, And Stress-Related Disorders
EP1954137A4 (en) * 2005-11-18 2008-12-17 Janssen Pharmaceutica Nv 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE
US20070155707A1 (en) * 2005-12-29 2007-07-05 Kadmus Pharmaceuticals, Inc. Ionizable inhibitors of fatty acid amide hydrolase
KR20080091132A (ko) * 2005-12-29 2008-10-09 엔.브이.오가논 지방산 아미드 가수분해 효소의 억제제
WO2007106706A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Cyclic urea compounds as soluble epoxide hydrolase inhibitors effective for the treatment of cardiovascular disorders
EP2023728A4 (en) * 2006-05-26 2010-11-24 Janssen Pharmaceutica Nv OXAZOLYLPIPERIDINES AS MODULATORS OF FATTY ACID AMIDHYDROLASE
WO2008021625A2 (en) * 2006-08-18 2008-02-21 N.V. Organon Combination faah inhibitor and analgesic, anti-inflammatory or anti-pyretic agent
US20080089845A1 (en) * 2006-09-07 2008-04-17 N.V. Organon Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo
WO2008063714A1 (en) * 2006-11-20 2008-05-29 N.V. Organon Metabolically-stabilized inhibitors of fatty acid amide hydrolase
EP2161997A4 (en) * 2007-05-31 2011-04-06 Scripps Research Inst TRICYCLIC INHIBITORS OF FATTY ACID AMIDHYDROLASE
CN102333568B (zh) * 2008-12-24 2016-01-20 比亚尔-珀特拉和Ca股份公司 药物化合物
US9072676B2 (en) 2010-05-25 2015-07-07 Symrise Ag Cyclohexyl carbamate compounds as skin and/or hair lightening actives
PT2433527E (pt) * 2010-09-28 2013-04-30 Gruppo Cimbali Spa Varinha automática melhorada de produção de espuma de leite
WO2014023325A1 (en) * 2012-08-06 2014-02-13 Fondazione Istituto Italiano Di Tecnologia Multitarget faah and cox inhibitors and therapeutical uses thereof
ITMI20131180A1 (it) 2013-07-15 2015-01-16 Fond Istituto Italiano Di Tecnologia O-alchil triazolil carbammati come inibitori di idrolasi delle ammidi degli acidi grassi (faah)
AR100387A1 (es) * 2014-02-18 2016-10-05 Basf Se Copolímeros que comprenden etileno, ésteres de vinilo y ésteres de ácido (met)acrílico, sus formulaciones y usos como depresor del punto de fluidez, inhibidor de cera y potenciador de flujo para petróleos crudos
CA2987067A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
CN108368414A (zh) 2015-12-11 2018-08-03 国立大学法人静冈大学 油胶凝剂
US10220061B1 (en) 2017-09-26 2019-03-05 Cynthia Denapoli Method of reducing stress and anxiety in equines
US10414721B1 (en) 2018-06-04 2019-09-17 University Of Bern Inhibitor of endocannabinoid cellular reuptake

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776197A (en) 1953-09-02 1957-01-01 Geigy Ag J R Compositions and methods of influencing the growth of plants
EP0279522A2 (en) 1987-01-22 1988-08-24 Ishikawajima-Harima Jukogyo Kabushiki Kaisha Apparatus for pouring molten metal
US4987233A (en) 1988-06-15 1991-01-22 Eli Lilly And Company Process for preparing herbicidal ureas and insecticidal carbamates and carbamate derivatives
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5559410A (en) 1992-12-17 1996-09-24 Valeo Systemes D'essuyage Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US5962012A (en) 1997-11-28 1999-10-05 Caleb Pharmaceuticals, Inc. Cholinergic antagonist patch
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2002087569A1 (en) 2001-04-27 2002-11-07 Bristol-Myers Squibb Company Bisarylimidazolyl fatty acid amide hydrolase inhibitors
US6531506B1 (en) 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
WO2003065989A2 (en) 2002-02-08 2003-08-14 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3084096A (en) * 1955-08-29 1963-04-02 Union Carbide Corp Indanyl n-methyl carbamate
US3275512A (en) * 1962-11-27 1966-09-27 Upjohn Co Process for treating inflammation with biphenylcarbamates
US3632631A (en) * 1967-09-08 1972-01-04 Ethyl Corp Sterically hindered bisphenyl carbamates
US3880908A (en) * 1972-01-24 1975-04-29 Standard Oil Co Urethane derivatives of polymethyl biphenyl useful as fungicides
DE2943480A1 (de) 1979-10-27 1981-05-07 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n,o-disubstituierten urethanen, sowie ihre verwendung als ausgangsmaterial zur herstellung von isocyanaten
HU197831B (en) 1984-12-20 1989-06-28 Chinoin Gyogyszer Es Vegyeszet Insecticide compositions containing alkenyl-oxy-phenyl-carbamat derivatives as active components and process for producing the active components
IL74497A (en) * 1985-03-05 1990-02-09 Proterra Ag Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives
IL95994A0 (en) * 1989-11-15 1991-07-18 American Home Prod Carbamate esters and pharmaceutical compositions containing them
US5112859A (en) * 1990-09-14 1992-05-12 American Home Products Corporation Biphenyl amide cholesterol ester hydrolase inhibitors
US5476944A (en) * 1991-11-18 1995-12-19 G. D. Searle & Co. Derivatives of cyclic phenolic thioethers
IT1271679B (it) 1994-07-18 1997-06-04 Mediolanum Farmaceutici Srl Derivati del fenilcarbammato atti all'impiego come anticolinesterasici
DE4430600A1 (de) * 1994-08-22 1996-02-29 Hoechst Schering Agrevo Gmbh Biphenyl-Derivate
JPH0892167A (ja) * 1994-09-21 1996-04-09 Idemitsu Kosan Co Ltd 芳香族炭酸ジエステルの製造方法
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
CA2206192A1 (en) * 1996-06-13 1997-12-13 F. Hoffmann-La Roche Ag Modulation of lc132 (opioid-like) receptor function
US5856537A (en) * 1996-06-26 1999-01-05 The Scripps Research Institute Inhibitors of oleamide hydrolase
US6150415A (en) 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
KR20000069028A (ko) * 1996-11-19 2000-11-25 와트 씨 데이빗, 해리 에이 루스제 피리도스티그민의 다가염 및 관련 화합물
US5925672A (en) 1996-12-06 1999-07-20 Neurosciences Research Foundation, Inc. Methods of treating mental diseases, inflammation and pain
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6251931B1 (en) * 1998-11-24 2001-06-26 The Scripps Research Institute Inhibitors of gap junction communication
US6414002B1 (en) * 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
US6359010B1 (en) * 1999-11-23 2002-03-19 Thomas D. Geracioti, Jr. Methods of treating anxiety and mood disorders with oleamide
AU7847901A (en) 2000-07-19 2002-02-05 Hoffmann La Roche Pyrrolidine derivatives as metalloprotease inhibitors
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
YU12003A (sh) * 2000-08-16 2006-05-25 F. Hoffmann-La Roche Ag. Novi derivati aminocikloheksana
DE60216830T2 (de) * 2001-02-06 2007-06-14 Pfizer Products Inc., Groton Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
CZ2004714A3 (cs) 2001-12-14 2004-10-13 Novoánordiskáa@S Sloučeniny a jejich použití ke snížení aktivity lipázy citlivé vůči hormonu
US6908939B2 (en) * 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
FR2843964B1 (fr) * 2002-08-29 2004-10-01 Sanofi Synthelabo Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique
MXPA05003715A (es) 2002-10-07 2005-09-30 Univ California Modulacion de ansiedad a traves de bloqueo de hidrolisis de anandamida.

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2776197A (en) 1953-09-02 1957-01-01 Geigy Ag J R Compositions and methods of influencing the growth of plants
EP0279522A2 (en) 1987-01-22 1988-08-24 Ishikawajima-Harima Jukogyo Kabushiki Kaisha Apparatus for pouring molten metal
US4987233A (en) 1988-06-15 1991-01-22 Eli Lilly And Company Process for preparing herbicidal ureas and insecticidal carbamates and carbamate derivatives
US5541061A (en) 1992-04-29 1996-07-30 Affymax Technologies N.V. Methods for screening factorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US5559410A (en) 1992-12-17 1996-09-24 Valeo Systemes D'essuyage Device for controlling the function of an electric starting motor for a windshield wiper of a rear window of an automotive vehicle and for supplying an electric motor particularly to activate the windshield
US5576220A (en) 1993-02-19 1996-11-19 Arris Pharmaceutical Corporation Thin film HPMP matrix systems and methods for constructing and displaying ligands
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US6531506B1 (en) 1996-08-13 2003-03-11 Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of hypertension
US5962012A (en) 1997-11-28 1999-10-05 Caleb Pharmaceuticals, Inc. Cholinergic antagonist patch
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2002087569A1 (en) 2001-04-27 2002-11-07 Bristol-Myers Squibb Company Bisarylimidazolyl fatty acid amide hydrolase inhibitors
WO2003065989A2 (en) 2002-02-08 2003-08-14 Bristol-Myers Squibb Company (oxime)carbamoyl fatty acid amide hydrolase inhibitors

Non-Patent Citations (31)

* Cited by examiner, † Cited by third party
Title
"Design of Prodrugs", 1985, ELSEVIER
"Remington's Pharmaceutical Sciences", 2000, WILLIAMS & WILKINS PA
BAUM, C&EN, vol. 18, January 1993 (1993-01-01), pages 33
BELTRAMO, M. ET AL., FEBS LETT., vol. 403, 1997, pages 263 - 267
BICKERDIKE, M.J. ET AL., EUR. J. PHARMACOL., vol. 271, 1994, pages 403 - 411
BOGER, D.L. ET AL., PROC. NATL. ACAD. SCI. U.S. A., vol. 97, 2000, pages 5044 - 5049
CALIGNANO, A. ET AL., NATURE, vol. 394, 1998, pages 277 - 281
CAMPBELL ET AL., J. ORG. CHEM., vol. 59, 1994, pages 658
CHAPERON, F. ET AL., CRIT. REV. NEUROBIOL., vol. 13, 1999, pages 243 - 281
CHEN ET AL., J. AMER. CHEM. SOC., vol. 116, 1994, pages 2661
CHO ET AL., SCIENCE, vol. 261, 1993, pages 1303
CRAVATT, B.F. ET AL., PROC. NATL. ACAD. SCI. U. S. A., vol. 98, 2001, pages 9371 - 9376
DE PETROCELLIS, L. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 231, 1997, pages 82 - 88
DEUTSCH, D.G. ET AL., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 231, 1997, pages 217 - 221
EFFENBERGER ET AL., CHEM. BER., vol. 105, 1972, pages 1926 - 1942
GALLOP ET AL., J. MED. CHEM., vol. 37, no. 9, 1994, pages 1233
HALL, W. ET AL., LANCET, vol. 352, 1998, pages 1611 - 1616
HOBBS ET AL., PROC. NATL. ACAD. SCI. USA., vol. 90, 1993, pages 6909
INSEL, T.R. ET AL., PHARMACOL. BIOCHEM. BEHAV., vol. 24, 1986, pages 1263 - 1267
KATHURIA ET AL., NATURE MEDICINE, vol. 9, no. 1, 2003, pages 76
KATHURIA ET AL., NATURE MEDICINE, vol. 9, no. 1, January 2003 (2003-01-01), pages 76 - 81
KAWAHARA ET AL., ORGANIC LETTERS, vol. 2, no. 5, 2000, pages 675 - 678
KOUTEK, B. ET AL., J. BIOL. CHEM., vol. 269, 1994, pages 22937 - 22940
MICZEK, K.A. ET AL., PSYCHOPHARMACOLOGY, vol. 121, 1995, pages 38 - 56
MORISSEAU ET AL., PROC. NATL. ACAD. SCI. USA, vol. 96, August 1999 (1999-08-01), pages 8849 - 88654
RODRIGUEZ DE FONSECA, F. ET AL., NATURE, vol. 414, 2001, pages 209 - 212
See also references of EP1558591A4
SHEPHERD, J.K. ET AL., PSYCHOPHARMACOLOGY, vol. 116, 1994, pages 56 - 64
SHOWALTER ET AL., J. PHARMACOL EXP THER., vol. 278, no. 3, 1996, pages 989 - 99
TARZIA ET AL., J. MED. CHEM., vol. 46, 2003, pages 2352 - 2360
WINSLOW, J.T. ET AL., BIOL. PSYCHIATRY, vol. 15, 1991, pages 745 - 757

Cited By (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006000324A3 (en) * 2004-06-23 2006-03-02 Hoffmann La Roche New mao-b inhibitors
US7253318B2 (en) 2004-06-23 2007-08-07 Hoffman-La Roche Inc. Benzyloxy derivatives as MAOB inhibitors
WO2006000324A2 (en) * 2004-06-23 2006-01-05 F. Hoffmann-La Roche Ag New mao-b inhibitors
KR100855618B1 (ko) * 2004-06-23 2008-09-01 에프. 호프만-라 로슈 아게 Mao-b 억제제
JP2008520740A (ja) * 2004-11-23 2008-06-19 ピーティーシー セラピューティクス, インコーポレイテッド Vegf産生を阻害する活性因子としての置換されたフェノール
EP2607362A1 (en) 2005-02-17 2013-06-26 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
TWI385152B (zh) * 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (I)
US7919495B2 (en) 2005-02-17 2011-04-05 Astellas Pharma, Inc. Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound
US7919494B2 (en) 2005-02-17 2011-04-05 Astellas Pharma, Inc. Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound
EP1849773A4 (en) * 2005-02-17 2011-06-15 Astellas Pharma Inc PYRIDYL (NON-AROMATED NITROGENATED HETEROCYCLIC 1-CARBOXYLATESTER) DERIVATIVE
US7915261B2 (en) 2005-02-17 2011-03-29 Astellas Pharma, Inc. Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate compound
TWI385164B (zh) * 2005-02-17 2013-02-11 Astellas Pharma Inc Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
AU2010202348B2 (en) * 2005-02-17 2011-07-21 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
EP1849773A1 (en) * 2005-02-17 2007-10-31 Astellas Pharma Inc. Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative
WO2008022976A1 (en) * 2006-08-21 2008-02-28 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of a faah inhibitor
US7888394B2 (en) 2006-08-21 2011-02-15 N.V. Organon Synthesis, polymorphs, and pharmaceutical formulation of FAAH inhibitors
WO2008023720A1 (fr) 2006-08-23 2008-02-28 Astellas Pharma Inc. COMPOSÉ D'URÉE OU SEL DUDIT COMPOSé
WO2008042892A3 (en) * 2006-10-02 2009-02-19 Organon Nv Fatty acid amide hydrolase inhibitors for energy metabolism disorders
WO2008042892A2 (en) * 2006-10-02 2008-04-10 N.V. Organon Fatty acid amide hydrolase inhibitors for energy metabolism disorders
WO2008100977A3 (en) * 2007-02-14 2008-12-18 Organon Nv Carbamates therapeutic release agents as amidase inhibitors
WO2008100977A2 (en) * 2007-02-14 2008-08-21 N.V. Organon Carbamates therapeutic release agents as amidase inhibitors
WO2008135041A1 (de) * 2007-05-08 2008-11-13 Schebo Biotech Ag Adamantyloxyamin-derivate und verwandte verbindungen als nmda und/oder dpp-4 modulatoren zur behandlung von zns-erkrankungen und diabetes
US8372823B2 (en) 2007-05-25 2013-02-12 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
WO2008147553A1 (en) * 2007-05-25 2008-12-04 The Scripps Research Institute Tetracyclic inhibitors of fatty acid amide hydrolase
US8207226B1 (en) 2008-06-03 2012-06-26 Alcon Research, Ltd. Use of FAAH antagonists for treating dry eye and ocular pain
WO2010007966A1 (ja) 2008-07-14 2010-01-21 アステラス製薬株式会社 アゾール化合物
US8207199B2 (en) 2008-07-14 2012-06-26 Astellas Pharma Inc. Azole compound
WO2010053120A1 (ja) 2008-11-06 2010-05-14 アステラス製薬株式会社 カルバメート化合物又はその塩
AU2009315448B2 (en) * 2008-11-14 2015-07-16 Sanofi-Aventis Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
WO2010055267A1 (fr) * 2008-11-14 2010-05-20 Sanofi-Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique
FR2938537A1 (fr) * 2008-11-14 2010-05-21 Sanofi Aventis Derives de carbamates d'alkyl-heterocycles, leur preparation et leur application en therapeutique.
EA019742B1 (ru) * 2008-11-14 2014-05-30 Санофи Карбаматные производные алкилгетероциклов, их получение и их применение в терапии
US8716289B2 (en) 2008-11-14 2014-05-06 Sanofi Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof
AU2010212235B2 (en) * 2009-02-05 2016-06-09 Sanofi Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
FR2941696A1 (fr) * 2009-02-05 2010-08-06 Sanofi Aventis Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique
WO2010089510A3 (fr) * 2009-02-05 2010-09-30 Sanofi-Aventis Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
US8889702B2 (en) 2009-02-05 2014-11-18 Sanofi Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof
WO2011030798A1 (ja) 2009-09-09 2011-03-17 大日本住友製薬株式会社 8-オキソジヒドロプリン誘導体
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US9000010B2 (en) 2010-01-20 2015-04-07 Sanofi Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application
FR2955580A1 (fr) * 2010-01-28 2011-07-29 Sanofi Aventis Derives de carbamate d'alkyl-heterocycles, leur preparation et leur application en therapeutique
WO2011123719A2 (en) 2010-03-31 2011-10-06 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating abdominal, visceral and pelvic pain
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
US20130137710A1 (en) * 2010-05-25 2013-05-30 Symrise Ag Cyclohexyl carbamate compounds as active anti-cellulite ingredients
US9012497B2 (en) * 2010-05-25 2015-04-21 Symrise Ag Cyclohexyl carbamate compounds as active anti-cellulite ingredients
US20130217764A1 (en) * 2010-07-28 2013-08-22 Daniele Piomelli Peripherally restricted faah inhibitors
US9187413B2 (en) * 2010-07-28 2015-11-17 The Regents Of The University Of California Peripherally restricted FAAH inhibitors
EP2744778A4 (en) * 2011-08-19 2015-04-08 Univ California PERIPHERICALLY RESTRICTED FAAH INHIBITORS SUBSTITUTED IN META POSITION BY A BIPHENYL
KR20150100485A (ko) * 2011-08-19 2015-09-02 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
EP2744778A2 (en) * 2011-08-19 2014-06-25 The Regents of the University of California Meta-substituted biphenyl peripherally restricted faah inhibitors
US9745255B2 (en) 2011-08-19 2017-08-29 The Regents Of The University Of California Meta-substituted biphenyl peripherally restricted FAAH inhibitors
KR102079404B1 (ko) * 2011-08-19 2020-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 메타-치환된 비페닐 말초 제한형 faah 억제제
WO2015007615A1 (en) * 2013-07-18 2015-01-22 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (faah) enzyme and modulators of the d3 dopamine receptor (d3dr)
US9828352B2 (en) 2013-07-18 2017-11-28 Fondazione Istituto Italiano Di Tecnologia Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR)
US9822068B2 (en) 2014-04-07 2017-11-21 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments
US10435355B2 (en) 2014-04-07 2019-10-08 The Regents Of The University Of California Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicaments
EP3129354B1 (en) * 2014-04-07 2022-01-05 The Regents of the University of California Inhibitors of fatty acid amide hydrolase (faah) enzyme with improved oral bioavailability and their use as medicaments

Also Published As

Publication number Publication date
EP1558591A2 (en) 2005-08-03
JP4515911B2 (ja) 2010-08-04
JP2006511484A (ja) 2006-04-06
US20120010283A1 (en) 2012-01-12
EP1558591B1 (en) 2014-05-07
WO2004033422A3 (en) 2004-07-29
AU2003279877A1 (en) 2004-05-04
CN1729171A (zh) 2006-02-01
EA010267B1 (ru) 2008-06-30
US20090048337A1 (en) 2009-02-19
AU2003279877B2 (en) 2010-05-20
EP1558591A4 (en) 2007-09-12
KR20050088992A (ko) 2005-09-07
CN100408556C (zh) 2008-08-06
US20040127518A1 (en) 2004-07-01
CA2501506C (en) 2014-02-11
CA2501506A1 (en) 2004-04-22
EA200500615A1 (ru) 2005-10-27
US8003693B2 (en) 2011-08-23
UA80841C2 (en) 2007-11-12
MXPA05003715A (es) 2005-09-30
US7176201B2 (en) 2007-02-13

Similar Documents

Publication Publication Date Title
AU2003279877B2 (en) Modulation of anxiety through blockade of anandamide hydrolysis
EP3055299B1 (en) Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
Lutz On-demand activation of the endocannabinoid system in the control of neuronal excitability and epileptiform seizures
JP6872541B2 (ja) [1,2,4]トリアゾロ[1,5−a]ピリミジン−7−イル化合物
US20070155747A1 (en) Inhibitors of fatty acid amide hydrolase
González-Muñoz et al. N-acylaminophenothiazines: Neuroprotective agents displaying multifunctional activities for a potential treatment of Alzheimer’s disease
US7671052B2 (en) Phenyl derivatives and methods of use
WO2008024139A2 (en) Inhibitors of fatty acid amide hydrolase
US20140163034A1 (en) Inhibitors of anandamide transport and their therapeutic uses
WO2023283386A2 (en) Safer psychoactive compositions
Choubey et al. Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer’s disease
EP1969051A2 (en) Inhibitors of fatty acid amide hydrolase
KR20130110160A (ko) 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체
JP6449297B2 (ja) 1,2,4−トリアゾロ[4,3−a]ピリジン化合物およびMGLUR2受容体の正のアロステリック調節因子としてのそれらの使用
WO2023028091A1 (en) Deuterated empathogens
US20200188392A1 (en) Treatment of epilepsy with plinabulin or halimade or diketopiperazine derivatives
JP2011518188A (ja) リソソーム調節のための化合物および使用方法
CN101594867B (zh) 与火蚁毒素相关的组合物,以及它们在制备治疗神经系统障碍和提高认知和体能药物中的用途
Silakari et al. Systematic in silico design, synthesis, and biological studies of some novel 1, 4-benzoquinone derivatives for the prospective management of cognitive decline
WO2023192675A1 (en) T-type calcium channel modulators comprising an azaspirononane core and methods of use thereof
WO2023028092A2 (en) Fluorinated empathogens
CA3232827A1 (en) Substituted phenylalkylamines
WO2024006226A1 (en) N-substituted phenylalkylamines and their use as therapeutic agents
WO2023192665A2 (en) T-type calcium channel modulators and methods of use thereof
WO2023192687A1 (en) T-type calcium channel modulators comprising an azaspiroheptane core and methods of use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2501506

Country of ref document: CA

Ref document number: 167888

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020057005995

Country of ref document: KR

Ref document number: 2004543510

Country of ref document: JP

Ref document number: PA/A/2005/003715

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2003279877

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003773201

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 811/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 200500615

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038A52130

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003773201

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057005995

Country of ref document: KR